Tip os
Log ind
Ole Larsen Bavarian.jpg

Bavarian: The clock is ticking for BMS

Top picks in English:

The first quarter went as expected for Denmark’s Bavarian Nordic. The clinical program with the prostate hope Prostvac will continue in progress. This means that the Danish company will also come closer to more millions from US company Bristol-Meyers Squibb. Meanwhile, the company’s CFO makes a plea to the world concerning the Zika virus.


BY STEFAN SINGH KAILAY
Offentliggjort 17.05.16 kl. 13:11

Log ind for at læse artikler

Velkommen til MedWatch. En del af vores indhold er eksklusivt og forbeholdt vores brugere.

Prøv os gratis i 14 dage

Få fuld adgang til vores kvalitetsjournalistik med et gratis prøveabonnement.

Sign up for MedWatch newsletter
Mest læste Top picks in English

Genmab accelerates research efforts

JanVanDerWinkel02.jpg Top picks in English:

Genmab will need to identify its next winning ticket in the coming three to four years, and its CEO is fully convinced that the drug is already hiding in the biotech company’s pipeline. The firm is now increasing its R&D budget in a bid to identify the winner.

Darzalex is still the “star of the show” for Genmab

Top picks in English:

Genmab’s Darzalex royalties now cover the company’s operating costs and in addition to that, the cancer drug continues its expansion to new markets. And according to CEO, Jan van de Winkel, Genmab could potentially raise its guidance this year.

Here is what Danish drug companies pay their workers

Top picks in English:

The average monthly salary in the private pharmaceutical industry in Denmark is DKK 57,109. Make the jump to find out which company pays the highest wages and learn how much the rest of the industry pays as well.

Novo expands its executive team

Top picks in English:

Novo Nordisk has promoted two of its regional directors to its executive management team, which has undergone a slew of changes in the past year.

Genmab CEO about wonder drug: ”It’s incredible”

Top picks in English:

Genmab has raised its guidance for the third time this year and it could be hiked once more before the close of 2016. The biotech’s CEO says sales of its oncology product Darzalex are “earth shattering” and already looks forward to presenting an heir to the budding blockbuster.

ALK CEO: We call the FDA on a daily basis

Top picks in English:

Denmark’s ALK is ready to go “full steam” in the launch of a promising tablet against house dust mite allergy on the US market as early as this year. The only obstacle is a formal handover of the marketing permit from former partner Merck, which could push the launch into 2018.

Forsiden lige nu

MedWatch-indeks: Regnskaber rev i forskellige retninger

Regnskab.jpg Medicinal & Biotek:

De to børsnoterede høreapparatselskaber ender i hver sin ende af MedWatch-indekset i en uge, hvor den igangværende regnskabssæson generelt førte til de største udsving på aktiemarkedet.

Disse selskaber hyrer og fyrer mest

Medicinal & Biotek:

Den samlede arbejdsstyrke i verdens største medicinalselskaber er blevet holdt nogenlunde i ro mellem 2015 og 2016. Men i de enkelte selskaber, herunder de to største aktører i Danmark, er der stor forskel på, om man hyrer eller fyrer.

Coloplast-boss: Hensættelser til søgsmål er passende

Medico & Rehab:

Adm. direktør i Coloplast, Lars Rasmussen, forventer, at selskabet snart har afsluttet de resterende produktansvarssager i USA.

Studie viser stor inkompetence blandt sundhedsvæsnets tolke

Sygdom & Sundhed:

Knap halvdelen af dansk-arabisk tolke i det danske sundhedsvæsen er ikke gode nok sprogligt. Det viser et endnu ikke offentliggjort studie. Danske Regioner erkender problemet

Det vil tage 1-2 år mere at fordoble sårforretningen hos Coloplast

Medico & Rehab:

Det er fortsat målet at fordoble sårplejeforretningen for medicoselskabet Coloplast - tidshorisonten har bare skubbet sig lidt, fortæller direktør for sårplejeforretningen.

Lundbeck-direktører udnytter optioner og tegner aktier til rabatpris

Medicinal & Biotek:

Forskningsdirektøren i medicinalselskabet Lundbeck har tegnet 160.000 aktier i selskabet for samlet 25 mio. kr.

ANNONCE
ANNONCE


ANNONCE